Compare Fidelity National Information Servcs Inc (FIS) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fidelity National Information Servcs Inc vs Organon & Co. Common Stock — how do they compare? Fidelity National Information Servcs Inc trades at $35.64 (market cap $18.15B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Fidelity National Information Servcs Inc is far larger — about 5× Organon & Co. Common Stock's market cap, and Fidelity National Information Servcs Inc pays the higher dividend (5%). Which is the better fit depends on your goals — on Pluang, investors hold Fidelity National Information Servcs Inc for 89 Days and Organon & Co. Common Stock for 0 Days on average.
| FIS | OGN | |
|---|---|---|
Market Cap | $18.15B | $3.62B |
Volume | 8,219,694 | 2,892,999 |
Sector | Technology | Health |
52-Week High | $67.94 | $13.81 |
52-Week Low | $32.44 | $5.70 |
Typical Hold Time | 89 Days | 0 Days |
Enterprise Value | $38.66B | $11.04B |
Dividend Yield | 5% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIS trades at $35.47, up 3.53% with strong earnings beats in recent quarters. The stock shows bearish technical signals despite positive analyst sentiment with 57% buy ratings and a $45.50 consensus target. Fundamentals improved significantly with net income turning positive at $382 million in 2025 after prior losses, while revenue growth is projected to reach $12.2 billion in 2026. Recent business wins include core banking platform adoptions and embedded finance innovations.
FIS presents a compelling value opportunity with low P/E of 5.4 and strong profitability metrics, though technical indicators suggest near-term caution. Key risks include debt management challenges and competitive pressures in financial technology. The 27% upside to analyst targets and ongoing business momentum support a constructive outlook for patient investors.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Fidelity National Information Servcs Inc
Fidelity National Information Services' legacy operations provide core and payment processing services to banks, but its business has expanded over time. By acquiring Sungard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS now provides payment processing services for merchants and holds leading positions in the United States and United Kingdom. About a fourth of revenue is generated outside North America.
Read more on FIS →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
